Lipid disorders

>

Latest News

RDX-002 Hits Primary and Secondary Endpoints for Post-GLP-1 Weight Management / image credit ©missbobbit/stock.adobe.com
RDX-002 Hits Primary and Secondary End Points for Post–GLP-1 Weight Management

August 14th 2025

RDX-002, an investigational, first-in-class therapeutic, significantly reduced weight regain after cessation of antiobesity treatment with semaglutide and tirzepatide.

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia /image credit ©muhammed/stock.adobe.com
FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

August 1st 2025

FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C
FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C

February 10th 2025

Strong Link Between Increasing Lp(a) Level and Recurrent ASCVD Events Makes Screening Essential, Investigator Warns /Image Seth J Baum
Strong Link Between Increasing Lp(a) Level and Recurrent ASCVD Events Makes Screening Essential, Investigator Warns

September 25th 2024

Dyslipidemia in American Indian Youth: Daily Dose / image credit: ©New Africa/AdobeStock
Dyslipidemia in American Indian Youth: Daily Dose

March 15th 2024

<1
...
1415161718
© 2025 MJH Life Sciences

All rights reserved.